Macrolide-Based Regimens and Mortality in Hospitalized Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis

被引:119
作者
Asadi, Leyla [1 ]
Sligl, Wendy I. [1 ,2 ]
Eurich, Dean T.
Colmers, Isabelle N. [3 ]
Tjosvold, Lisa [4 ]
Marrie, Thomas J. [6 ]
Majumdar, Sumit R. [5 ]
机构
[1] Univ Alberta, Div Infect Dis, Edmonton, AB T6G 2B7, Canada
[2] Univ Alberta, Div Crit Care Med, Edmonton, AB T6G 2B7, Canada
[3] Univ Alberta, Dept Publ Hlth Sci, Sch Publ Hlth, Edmonton, AB T6G 2B7, Canada
[4] Univ Alberta, John W Scott Hlth Sci Lib, Edmonton, AB T6G 2B7, Canada
[5] Univ Alberta, Fac Med & Dent, Dept Med, Edmonton, AB T6G 2B7, Canada
[6] Dalhousie Univ, Fac Med, Dept Med, Halifax, NS, Canada
基金
加拿大健康研究院;
关键词
LENGTH-OF-STAY; ELDERLY-PATIENTS; BETA-LACTAM; THERAPY; GUIDELINES; OUTCOMES; IMPACT; MANAGEMENT; SEPSIS; ADULTS;
D O I
10.1093/cid/cis414
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Background. Macrolides are used to treat pneumonia despite increasing antimicrobial resistance. However, the immunomodulatory properties of macrolides may have a favorable effect on pneumonia outcomes. Therefore, we systematically reviewed all studies of macrolide use and mortality among patients hospitalized with community-acquired pneumonia (CAP). Methods. All randomized control trials (RCTs) and observational studies comparing macrolides to other treatment regimens in adults hospitalized with CAP were identified through electronic databases and gray literature searches. Primary analysis examined any macrolide use and mortality; secondary analysis compared Infectious Diseases Society of America/American Thoracic Society guideline-concordant macrolide/beta-lactam combinations vs respiratory fluoroquinolones. Random effects models were used to generate pooled risk ratios (RRs) and evaluate heterogeneity (I-2). Results. We included 23 studies and 137 574 patients. Overall, macrolide use was associated with a statistically significant mortality reduction compared with nonmacrolide use (3.7% [1738 of 47 071] vs 6.5% [5861 of 90 503]; RR, 0.78; 95% confidence interval [CI], .64-.95; P = .01; I-2 = 85%). There was no survival advantage and heterogeneity was reduced when analyses were restricted to RCTs (4.6% [22 of 479] vs 4.1% [25 of 613]; RR, 1.13; 95% CI, .65-1.98; P = .66; I-2 = 0%) or to patients treated with guideline-concordant antibiotics (macrolide/beta-lactam, 5.3% [297 of 5574] vs respiratory fluoroquinolones, 5.8% [408 of 7050]; RR, 1.17; 95% CI, .91-1.50; P = .22; I-2 = 43%). Conclusions. In hospitalized patients with CAP, macrolide-based regimens were associated with a significant 22% reduction in mortality compared with nonmacrolides; however, this benefit did not extend to patients studied in RCTs or patients that received guideline-concordant antibiotics. Our findings suggest guideline concordance is more important than choice of antibiotic when treating CAP.
引用
收藏
页码:371 / 380
页数:10
相关论文
共 41 条
[2]
[Anonymous], 2008, EUR RESPIR J, DOI DOI 10.1183/09031936.00092607
[3]
[Anonymous], EUR J CLIN PHARM
[4]
Improving Outcomes in Elderly Patients With Community-Acquired Pneumonia by Adhering to National Guidelines Community-Acquired Pneumonia Organization International Cohort Study Results [J].
Arnold, Forest W. ;
LaJoie, A. Scott ;
Brock, Guy N. ;
Peyrani, Paula ;
Rello, Jordi ;
Menendez, Rosario ;
Lopardo, Gustavo ;
Torres, Antoni ;
Rossi, Paolo ;
Ramirez, Julio A. .
ARCHIVES OF INTERNAL MEDICINE, 2009, 169 (16) :1515-1524
[5]
Impact of guideline-concordant antibiotics and macrolide/-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study [J].
Asadi, L. ;
Eurich, D. T. ;
Gamble, J. M. ;
Minhas-Sandhu, J. K. ;
Marrie, T. J. ;
Majumdar, S. R. .
CLINICAL MICROBIOLOGY AND INFECTION, 2013, 19 (03) :257-264
[6]
Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia [J].
Brandenburg, JA ;
Marrie, TJ ;
Coley, CM ;
Singer, DE ;
Obrosky, DS ;
Kapoor, WN ;
Fine, MJ .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2000, 15 (09) :638-646
[7]
Initial Antibiotic Selection and Patient Outcomes: Observations from the National Pneumonia Project [J].
Bratzler, Dale W. ;
Ma, Allen ;
Nsa, Wato .
CLINICAL INFECTIOUS DISEASES, 2008, 47 :S193-S201
[8]
Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia - Analysis of a hospital claims-made database [J].
Brown, RB ;
Iannini, P ;
Gross, P ;
Kunkel, M .
CHEST, 2003, 123 (05) :1503-1511
[9]
Empiric treatment in hospitalized community-acquired pneumonia.: Impact on mortality, length of stay and re-admission [J].
Calzada, S. Reyes ;
Tomas, R. Martinez ;
Romero, M. J. Cremades ;
Moragon, E. Martinez ;
Cataluna, J. J. Soler ;
Villanueva, R. Menendez .
RESPIRATORY MEDICINE, 2007, 101 (09) :1909-1915
[10]
Immunomodulatory activities of fluoroquinolones [J].
Dalhoff, A .
INFECTION, 2005, 33 (Suppl 2) :55-70